Reviewing Many Bright Ideas Technologies (OTCMKTS:MBGNF) and 10x Genomics (NASDAQ:TXG)

Many Bright Ideas Technologies (OTCMKTS:MBGNF) and 10x Genomics (NASDAQ:TXG) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, dividends, risk, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings for Many Bright Ideas Technologies and 10x Genomics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Many Bright Ideas Technologies	0	0	0	0	0.00
10x Genomics	1	11	5	0	2.24

10x Genomics has a consensus target price of $40.57, indicating a potential downside of 34.19%. Given 10x Genomics’ stronger consensus rating and higher possible upside, analysts clearly believe 10x Genomics is more favorable than Many Bright Ideas Technologies.

Profitability

This table compares Many Bright Ideas Technologies and 10x Genomics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Many Bright Ideas Technologies	N/A	N/A	N/A
10x Genomics	-12.18%	-9.33%	-7.30%

Earnings & Valuation

This table compares Many Bright Ideas Technologies and 10x Genomics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Many Bright Ideas Technologies	N/A	N/A	N/A	N/A	N/A
10x Genomics	$642.82 million	12.50	-$43.54 million	($0.59)	-104.49

Many Bright Ideas Technologies has higher earnings, but lower revenue than 10x Genomics.

Institutional & Insider Ownership

84.7% of 10x Genomics shares are held by institutional investors. 8.8% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

10x Genomics beats Many Bright Ideas Technologies on 6 of the 9 factors compared between the two stocks.

About Many Bright Ideas Technologies

Many Bright Ideas Technologies Inc. does not have significant operations. It was previously engaged in the life science business with a focus on the commercialization of prognostic genomic-based tests for non-small-cell lung cancer. It focuses on the commercialization of technologies in various industrial sectors. The company is headquartered in Vancouver, Canada.

About 10x Genomics

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.